SRX246: Phase II data

The double-blind, U.S. Phase II AVN009 trial in 97 adults with intermittent explosive disorder showed that twice-daily 120 mg oral SRX246 for 4 weeks followed by twice-daily 160 mg oral SRX246 for 4 w...